Resource utilization in patients with breast cancer treated with generic versus branded docetaxel.

1015 Background: This study was to assess health resource utilization in patients with breast cancer (BC) treated with generic (available in US since 2011) vs branded docetaxel. Methods: A retrospective inception cohort was analyzed in Clinformatics DataMart healthcare claims database. Patients (female, aged ≥18 years) were identified between Apr 1, 2011 and Jun 30, 2012 if they had an ICD-9:174 for BC, initiated docetaxel, and had 6-month continuous insurance coverage pre (baseline) and post (follow-up) docetaxel initiation. The 50 most frequent claims for clinical diagnoses, procedures and prescriptions were evaluated between generic and branded docetaxel along with health resource utilization and expenditures, with hierarchical mixed effects model adjustment for potential confounding. Results: 1,955 patients diagnosed with BC were identified, of which a total of 98 generic and 262 branded docetaxel users were included in the final analysis. For the majority of patients, the source of docetaxel was not ...